MAY 2SessionsSunday Evening6:00 PM – 7:30 PM • Mercury Ballroom1 Hypertension <strong>and</strong> Oxidative StressChairs: Gregory D. Fink, MD, East Lansing, MI <strong>and</strong>Rhian M. Touyz, MD, PhD, Ottawa, CanadaOriginal Communications6:00 PM OR-1: Regulation of Renal Inflammation byDopamine D2 ReceptorsInes Arm<strong>and</strong>o†, Yanrong Zhang, Yu Yang, XioayanWang, John E. Jones, Laureano D. Asico, CrisantoEscano, Pedro A. Jose. Children’s Research Institute,Washington, DC, US.6:15 PM OR-2: Hyperuricemia Induces Oxidative Stress<strong>and</strong> Decreased Nitric Oxide Availability via theAngiotensin Type 1 ReceptorDalila Corry, 1 Janake Wijesuriya†, 2 Michael D. Nyby, 2Victoria Smutko, 2 Michael L. Tuck. 2 1 David GeffenSchool of Medicine at UCLA, Sylmar, CA, US <strong>and</strong>2 David Geffen School of Medicine at UCLA/VAGLAHS, Sepulveda, CA, US.6:30 PM OR-3: Temporal Hemodynamic Changes PostMyocardial Infarction in Relation to CentralAlterations in Angiotensin II <strong>and</strong> Oxidative StressTarek M. Mousa, 1 Irving H. Zucker. 2 1 The New YorkHospital Medical Center of Queens, Flushing, NY,US <strong>and</strong> 2 University of Nebraska Medical Center-Cardiovascular Research Center, Omaha, NE, US.6:45 PM OR-4: Novel Angiotensinogen Gene PromoterVariants And Kidney CancerRiccardo Sarzani, 1 Marica Bordicchia, 1 Marcod’Anzeo, 1 Guido Salvetti, 2 Ferruccio Santini, 2 AntonioBarbato, 3 Pasquale Strazzullo, 3 Paolo Dessì-Fulgheri, 1Alless<strong>and</strong>ro Rappelli. 1 1 Dept of Internal Medicine,University of Ancona - Politecnica Marche, Ancona,IT; 2 Endocrinology <strong>and</strong> Kidney Unit, UniversityHospital, Pisa, IT <strong>and</strong> 3 Dept. of Clinical <strong>and</strong>Experimental Medicine-University Naples, Napoli, IT.7:00 PM Oxidative Stress <strong>and</strong> HypertensionChristopher S. Wilcox, MD, PhD, Washington, DC1 Pathobiology Track 2 Translational Track 3 Therapy Track76
Sunday Evening MAY 2Sessions6:00 PM – 7:15 PM • East Ballroom2 Blood Pressure Goals: Novel ApproachesChairs: Roger S. Blumenthal, MD, Baltimore, MD <strong>and</strong>Murray Epstein, MD, Miami, FLOriginal Communications6:00 PM OR-5: Triple Combination Therapy withAmlodipine/Valsartan/HCTZ at Maximal DosesIs Safe <strong>and</strong> Effective for Hypertensive PatientsUncontrolled on ARB Monotherapy: The EXTRAStudyS. Oparil†, 1 T. Giles, 2 E. Ofili, 3 B. Pitt, 4 Y. Seifu, 5R. Samuel, 5 R. Hilkert, 5 J. Sowers. 6 1 Univ. Alabama atBirmingham, US; 2 Tulane Univ. SoM, US; 3 MorehouseSoM, US; 4 Univ. Michigan SoM, US; 5 Novartis, US <strong>and</strong>6 Univ. Missouri SoM, US.6:15 PM OR-6: Trends in Antihypertensive Medication UseAmong Incident Cases Of Hypertension, 2002-2006:The Geisinger Clinic PopulationFrederick J. Bloom, 1 Robert D. Langer, 2 Jove Graham, 1Raymond R. Townsend, 3 Sean Hennessy. 3 1 GeisingerHealth System, Danville, PA, US; 2 Jackson HoleCenter for Preventive Medicine, US <strong>and</strong> 3 University ofPennsylvania, US.6:30 PM OR-8: Improved Non-Fatal CardiovascularEvents with Chlorthalidone Compared toHydrochlorothiazideMichael P. Dorsch, 1,2 Steven R. Erickson, 1,2 Barry E.Bleske, 1,2 Alan B. Weder. 1,3 1 University of MichiganHospitals, Ann Arbor, MI, US; 2 University of MichiganCollege of Pharmacy, Ann Arbor, MI, US <strong>and</strong>3 University of Michigan Medical School, Ann Arbor,MI, US.6:45 PM Adherence to TherapyWilliam J. Elliott, MD, PhD, Yakima, WA1 Pathobiology Track 2 Translational Track 3 Therapy Track77
- Page 1 and 2:
American Society of Hypertension201
- Page 3 and 4:
Valturna offers bothsuperior BP eff
- Page 5 and 6:
Figure 2: Probability of Achieving
- Page 7 and 8:
potential for other drugs acting on
- Page 9 and 10:
aliskiren arms were about one-third
- Page 11 and 12:
As with other drugs that block angi
- Page 13:
American Society of Hypertension201
- Page 18:
Program Color KeyThe pages of this
- Page 21 and 22:
General InformationThis program boo
- Page 23 and 24:
General Information continuedHilton
- Page 25 and 26:
General Information continuedASH Sc
- Page 27 and 28: General Information continuedASH Hy
- Page 29 and 30: 2010 ASH Corporate MembersBoehringe
- Page 31 and 32: ASH Leadership2009-2010 Board of Di
- Page 33 and 34: Special LectureMonday, May 3, 2010,
- Page 35 and 36: Special LectureMonday, May 3, 2010,
- Page 37 and 38: 2010 Abstract Reviewers continuedEr
- Page 39 and 40: Visit TEKTURNA at Booth 1100.and/or
- Page 41 and 42: 5.5 HyperkalemiaIncreases in serum
- Page 43 and 44: with Pgp substrates or weak to mode
- Page 45 and 46: ASH Program at a GlanceSaturday, Ma
- Page 47 and 48: ASH Program at a GlanceMonday, May
- Page 49 and 50: Poster Category PresentationPosters
- Page 51 and 52: 2010 ASH Faculty continuedJeffrey R
- Page 53 and 54: 2010 ASH Faculty continuedAndrew Wh
- Page 55 and 56: 2010American Societyof Hypertension
- Page 57 and 58: Saturday Afternoon MAY 1PostersPost
- Page 59 and 60: Saturday Afternoon MAY 1Sessions3:3
- Page 61 and 62: Saturday Afternoon MAY 1Sessions3:3
- Page 63 and 64: Sunday Morning MAY 2Satellite Sympo
- Page 65 and 66: Sunday Morning MAY 2Sessions contin
- Page 67 and 68: Sunday Morning MAY 2Sessions8:00 AM
- Page 69 and 70: Sunday Morning MAY 2Sessions10:00 A
- Page 71 and 72: Sunday Morning MAY 2Sessions10:00 A
- Page 73 and 74: Sunday Afternoon MAY 2Sessions3:30
- Page 75 and 76: Sunday Afternoon MAY 2Sessions3:30
- Page 77: Sunday Afternoon MAY 2Special Sessi
- Page 81 and 82: Sunday Evening MAY 2Sessions6:00 PM
- Page 83 and 84: Monday Morning MAY 3Satellite Sympo
- Page 85 and 86: Monday Morning MAY 3Sessions8:00 AM
- Page 87 and 88: Monday Morning Afternoon MAY 21 3Po
- Page 89 and 90: Monday Morning MAY 3Sessions10:00 A
- Page 91 and 92: Monday Morning MAY 3Sessions10:00 A
- Page 93 and 94: Monday Morning MAY 3Sessions11:45 A
- Page 95 and 96: Monday Evening May 3Satellite Sympo
- Page 97 and 98: Tuesday Morning May 48:45 AM LB-OR-
- Page 99 and 100: Tuesday Morning May 4Sessions8:00 A
- Page 101 and 102: Tuesday Morning MAY 4ASH Membership
- Page 103 and 104: Tuesday Morning MAY 4Sessions10:55
- Page 105 and 106: 2010American Societyof Hypertension
- Page 107 and 108: Saturday Afternoon MAY 1Posters3:00
- Page 109 and 110: Saturday Afternoon MAY 1PostersPO-2
- Page 111 and 112: Saturday Afternoon MAY 1PostersPO-3
- Page 113 and 114: Saturday Afternoon MAY 1PostersPO-4
- Page 115 and 116: Saturday Afternoon MAY 1PostersPO-5
- Page 117 and 118: Saturday Afternoon MAY 1PostersPO-7
- Page 119 and 120: Saturday Afternoon MAY 1PostersPO-8
- Page 121 and 122: Saturday Afternoon MAY 1PostersPO-9
- Page 123 and 124: Saturday Afternoon MAY 1PostersPO-1
- Page 125 and 126: Sunday Morning MAY 2PostersPosters
- Page 127 and 128: Sunday Morning MAY 2Posters9:00 AM
- Page 129 and 130:
Sunday Morning MAY 2PostersPO-123:
- Page 131 and 132:
Sunday Morning MAY 2PostersPO-137:
- Page 133 and 134:
Sunday Morning MAY 2PostersPO-150:
- Page 135 and 136:
Sunday Morning MAY 2PostersPO-163:
- Page 137 and 138:
Sunday Morning MAY 2PostersPO-178:
- Page 139 and 140:
Sunday Morning MAY 2PostersPO-193:
- Page 141 and 142:
Sunday Morning MAY 2PostersPO-206:
- Page 143 and 144:
Monday Morning Afternoon MAY 21 3Po
- Page 145 and 146:
Monday Morning Afternoon MAY 21 3Po
- Page 147 and 148:
Monday Morning Afternoon MAY 21 3Po
- Page 149 and 150:
Monday Morning Afternoon MAY 21 3Po
- Page 151 and 152:
Monday Morning Afternoon MAY 21 3Po
- Page 153 and 154:
Monday Morning Afternoon MAY 21 3Po
- Page 155 and 156:
Monday Morning Afternoon MAY 21 3Po
- Page 157 and 158:
Monday Morning Afternoon MAY 21 3Po
- Page 159 and 160:
Monday Morning Afternoon MAY 21 3Po
- Page 161 and 162:
Monday Morning Afternoon May 213Pos
- Page 163 and 164:
Faculty Disclosure ListingGail Adle
- Page 165 and 166:
Faculty Disclosure Listing continue
- Page 167 and 168:
Faculty Disclosure Listing continue
- Page 169 and 170:
Faculty Disclosure Listing continue
- Page 171 and 172:
Faculty Disclosure Listing continue
- Page 173 and 174:
you to attend thethe Innovations Th
- Page 175 and 176:
5.5 HyperkalemiaIncreases in serum
- Page 177 and 178:
with Pgp substrates or weak to mode
- Page 179 and 180:
Valturna (aliskiren and valsartan,
- Page 181 and 182:
4 CONTRAINDICATIONSNone.5 WARNINGS
- Page 183 and 184:
een reported. In a 4-day trial of v
- Page 185 and 186:
7 DRUG INTERACTIONSNo drug interact
- Page 187 and 188:
8.5 Geriatric UseIn 8.5the Geriatri
- Page 189 and 190:
2010 ASH ExhibitorsASH Hypertension
- Page 191 and 192:
ASH Hypertension Resource CenterHil
- Page 193 and 194:
2010 ASH Exhibitors continuedCVRx I
- Page 195 and 196:
2010 ASH Exhibitors continuedIntern
- Page 197 and 198:
2010 ASH Exhibitors continuedNature
- Page 199 and 200:
2010 ASH Exhibitors continuedRESPeR
- Page 201 and 202:
Author IndexAAbaunza, Ricardo, 122A
- Page 203 and 204:
Author IndexCastellano, Maurizio, 1
- Page 205 and 206:
Author IndexGuarneri, Marco, 146Guo
- Page 207 and 208:
Author IndexLekakis, John, 118, 122
- Page 209 and 210:
Author IndexPittaras, Andreas, 149P
- Page 211 and 212:
Author IndexTello, Susana, 109, 135
- Page 213 and 214:
Hilton New York Floor PlansSecond F
- Page 215 and 216:
Hilton New York Floor PlansFourth F
- Page 218:
Are You 1in 3?Get the facts. Know y